Download PDF
Neurology International Open 2017; 01(04): E275-E286
DOI: 10.1055/s-0043-108836
Review
© Georg Thieme Verlag KG Stuttgart · New York

Acute Management of Anticoagulation-Associated Intracerebral Hemorrhage

Joji B. Kuramatsu
1   University Hospital Erlangen – Department of Neurology
,
Stefan T. Gerner
1   University Hospital Erlangen – Department of Neurology
,
Hagen B. Huttner
1   University Hospital Erlangen – Department of Neurology
,
Stefan Schwab
1   University Hospital Erlangen – Department of Neurology
› Author Affiliations
Further Information

Publication History

Publication Date:
17 October 2017 (online)

   Permissions and Reprints

Abstract

The incidence of anticoagulation-associated intracerebral hemorrhage (OAC-ICH) is increasing along with demographic changes and patients requiring oral anticoagulation for atrial fibrillation. OAC-ICH is one of the most detrimental sub-types of hemorrhagic stroke, characterized by larger hemorrhage volumes, more frequent intraventricular hemorrhage, increased and prolonged hematoma enlargement. The impact of these outcome predictors’ results in greater mortality rates and larger numbers of patients left in functionally dependent states after ICH. Yet, evidence on treatment options for these severely affected patients remains limited, resulting in weak recommendations by international and European guidelines. Minimization of hematoma enlargement constitutes the main focus of acute care, possibly achieved by blood pressure and reversal management. In all OAC-ICH patients irrespective of anticoagulation agent, immediate and aggressive blood pressure reductions as fast as possible targeting systolic blood pressure levels of 140 mmHg (at least within 4–6 h) seems reasonable. Specifically, in vitamin-K-associated ICH, blood pressure reductions have been shown to be associated with reduced rates of hematoma enlargement. Reversal management in OAC-ICH should be carried out as quickly as possible, though accounting for the different anticoagulation agents used. In vitamin-K-associated ICH, recent large-sized multicenter investigations contributed to refining reversal strategies. One German-wide cohort study including roughly 1 200 patients identified for the first time beneficial target values to guide reversal treatment. Anticoagulation reversal should achieve INR values of less than 1.3 or 1.2 at least within 4 h after admission. Agents to be used comprise prothrombin complex concentrates (PCC), which may achieve faster and more complete reversal. This combined approach (blood pressure management and INR-reversal) was associated with significant reductions of hematoma enlargement and lower in-hospital mortality rates. For dabigatran-related bleeding complications, most recently an antidote (Idarucizumab) has been approved, which has been prospectively investigated and showed rapid and almost complete reversal as well as sufficient hemostasis. Currently, bleeding under the influence of factor-Xa inhibitors poses great difficulties because no antidote is available and efficacy of commonly used antagonizing agents, i. e., PCC or fresh-frozen plasma (FFP), has not been proven for clinical use. The main aim of the present review focuses on acute-care management of OAC-ICH and tries to depict treatment options based on the most current data. Moreover, current neurocritical-care therapies for ICH will be reviewed to identify relevant implications specific to OAC-ICH treatment.

Key words

intracerebral hemorrhage - anticoagulation - hematoma enlargement - blood pressure reductions - reversal
 

  • References

  • 1 Hemphill 3rd JC, Greenberg SM, Anderson CS. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032-2060
    CrossrefPubMedGoogle Scholar
  • 2 Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet 2009; 373: 1632-1644
    CrossrefPubMedGoogle Scholar
  • 3 Sacco S, Marini C, Toni D. et al. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40: 394-399
    CrossrefPubMedGoogle Scholar
  • 4 Biffi A, Battey TW, Ayres AM. et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology 2011; 77: 1840-1846
    CrossrefPubMedGoogle Scholar
  • 5 Flaherty ML, Tao H, Haverbusch M. et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71: 1084-1089
    CrossrefPubMedGoogle Scholar
  • 6 Flibotte JJ, Hagan N, O’Donnell J. et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-1064
    CrossrefPubMedGoogle Scholar
  • 7 Rosand J, Eckman MH, Knudsen KA. et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880-884
    CrossrefPubMedGoogle Scholar
  • 8 Frontera JA, Lewin 3rd JJ, Rabinstein AA. et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: A statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24: 6-46
    CrossrefPubMedGoogle Scholar
  • 9 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
    CrossrefPubMedGoogle Scholar
  • 10 Kuramatsu JB, Gerner ST, Schellinger PD. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836
    CrossrefPubMedGoogle Scholar
  • 11 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
    CrossrefPubMedGoogle Scholar
  • 12 Steiner T, Al-Shahi Salman R, Beer R. et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014; 9: 840-855
    CrossrefPubMedGoogle Scholar
  • 13 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016; DOI: 10.1093/eurheartj/ehw058.
    CrossrefPubMedGoogle Scholar
  • 14 Krishnamurthi RV, Feigin VL, Forouzanfar MH. et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: Findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1: e259-e281
    CrossrefPubMedGoogle Scholar
  • 15 Nielsen PB, Larsen TB, Skjoth F. et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: A nationwide cohort study. Circulation 2015; 132: 517-525
    CrossrefPubMedGoogle Scholar
  • 16 Schols AM, Schreuder FH, van Raak EP. et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke 2014; 45: 268-270
    CrossrefPubMedGoogle Scholar
  • 17 Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-1477
    CrossrefPubMedGoogle Scholar
  • 18 Flaherty ML, Kissela B, Woo D. et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68: 116-121
    CrossrefPubMedGoogle Scholar
  • 19 Rosand J, Muzikansky A, Kumar A. et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005; 58: 459-462
    CrossrefPubMedGoogle Scholar
  • 20 Greenberg SM, Al-Shahi Salman R, Biessels GJ. et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 2014; 13: 419-428
    CrossrefPubMedGoogle Scholar
  • 21 Patel NJ, Deshmukh A, Pant S. et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: Implications for healthcare planning. Circulation 2014; 129: 2371-2379
    CrossrefPubMedGoogle Scholar
  • 22 Caldeira D, Rodrigues FB, Barra M. et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: A systematic review and meta-analysis. Heart 2015; 101: 1204-1211
    CrossrefPubMedGoogle Scholar
  • 23 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696
    CrossrefPubMedGoogle Scholar
  • 24 Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: A systematic review and meta-analysis. PLoS One 2015; 10: e0137444
    CrossrefPubMedGoogle Scholar
  • 25 Claassen DO, Kazemi N, Zubkov AY. et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol 2008; 65: 1313-1318
    PubMedGoogle Scholar
  • 26 Molina CA, Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage: Little evidence facing big fears. Stroke 2011; 42: 3665-3666
    CrossrefPubMedGoogle Scholar
  • 27 Biffi A, Anderson CD, Battey TW. et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 2015; 314: 904-912
    CrossrefPubMedGoogle Scholar
  • 28 AlKherayf F, Xu Y, Gandara E. et al. Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: Systematic review and meta-analysis. Thromb Res 2016; 144: 152-157
    CrossrefPubMedGoogle Scholar
  • 29 Apostolakis S, Lane DA, Guo Y. et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 861-867
    CrossrefPubMedGoogle Scholar
  • 30 Apostolakis S, Lane DA, Buller H. et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110: 1074-1079
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026
    CrossrefPubMedGoogle Scholar
  • 32 Stein M, Misselwitz B, Hamann GF. et al. Intracerebral hemorrhage in the very old: Future demographic trends of an aging population. Stroke 2012; 43: 1126-1128
    CrossrefPubMedGoogle Scholar
  • 33 Hankey GJ, Stevens SR, Piccini JP. et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: The rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014; 45: 1304-1312
    CrossrefPubMedGoogle Scholar
  • 34 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372
    CrossrefPubMedGoogle Scholar
  • 35 Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: Current status, special situations, and unmet needs. Lancet 2015; 386: 303-310
    CrossrefPubMedGoogle Scholar
  • 36 Smith EE, Eichler F. Cerebral amyloid angiopathy and lobar intracerebral hemorrhage. Arch Neurol 2006; 63: 148-151
    CrossrefPubMedGoogle Scholar
  • 37 Schneider JA. The cerebral cortex in cerebral amyloid angiopathy. Lancet Neurol 2016; 15: 778-779
    CrossrefPubMedGoogle Scholar
  • 38 Lovelock CE, Cordonnier C, Naka H. et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies. Stroke 2010; 41: 1222-1228
    CrossrefPubMedGoogle Scholar
  • 39 van Etten ES, Auriel E, Haley KE. et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke 2014; 45: 2280-2285
    CrossrefPubMedGoogle Scholar
  • 40 O’Donnell HC, Rosand J, Knudsen KA. et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342: 240-245
    CrossrefPubMedGoogle Scholar
  • 41 Hemphill 3rd JC, Farrant M, Neill Jr. TA. Prospective validation of the ICH Score for 12-month functional outcome. Neurology 2009; 73: 1088-1094
    CrossrefPubMedGoogle Scholar
  • 42 Rost NS, Smith EE, Chang Y. et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke 2008; 39: 2304-2309
    CrossrefPubMedGoogle Scholar
  • 43 Hemphill 3rd JC, Bonovich DC, Besmertis L. et al. The ICH score: A simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001; 32: 891-897
    CrossrefPubMedGoogle Scholar
  • 44 Parry-Jones AR, Abid KA, Di Napoli M. et al. Accuracy and clinical usefulness of intracerebral hemorrhage grading scores: A direct comparison in a UK population. Stroke 2013; 44: 1840-1845
    CrossrefPubMedGoogle Scholar
  • 45 Koennecke HC, Belz W, Berfelde D. et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011; 77: 965-972
    CrossrefPubMedGoogle Scholar
  • 46 Ziai WC, Tuhrim S, Lane K. et al. A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). Int J Stroke 2014; 9: 536-542
    CrossrefPubMedGoogle Scholar
  • 47 Broderick JP, Brott TG, Duldner JE. et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24: 987-993
    CrossrefPubMedGoogle Scholar
  • 48 Wang X, Arima H, Al-Shahi Salman R. et al. Clinical prediction algorithm (BRAIN) to determine risk of hematoma growth in acute intracerebral hemorrhage. Stroke 2015; 46: 376-381
    CrossrefPubMedGoogle Scholar
  • 49 Brouwers HB, Chang Y, Falcone GJ. et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol 2014; 71: 158-164
    CrossrefPubMedGoogle Scholar
  • 50 Purrucker JC, Haas K, Rizos T. et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol 2016; 73: 169-177
    CrossrefPubMedGoogle Scholar
  • 51 Anderson CS, Huang Y, Wang JG. et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): A randomised pilot trial. The Lancet Neurology 2008; 7: 391-399
    CrossrefPubMedGoogle Scholar
  • 52 Qureshi AI, Palesch YY, Martin R. et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 2010; 67: 570-576
    CrossrefPubMedGoogle Scholar
  • 53 Butcher KS, Jeerakathil T, Hill M. et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke 2013; 44: 620-626
    CrossrefPubMedGoogle Scholar
  • 54 Anderson CS, Heeley E, Huang Y. et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-2365
    CrossrefPubMedGoogle Scholar
  • 55 Qureshi AI, Palesch YY, Barsan WG. et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375: 1033-1043
    CrossrefPubMedGoogle Scholar
  • 56 (CHMP), E.M.A.-C.f.M.P.f.H.U.. Nicardipine-containing medicinal products for intravenous use. 2013
    PubMed
  • 57 Sarode R, Milling Jr. TJ, Refaai MA. et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-1243
    CrossrefPubMedGoogle Scholar
  • 58 Goldstein JN, Refaai MA, Milling Jr. TJ. et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385: 2077-2087
    CrossrefPubMedGoogle Scholar
  • 59 Steiner T, Poli S, Griebe M. et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15: 566-573
    CrossrefPubMedGoogle Scholar
  • 60 Parry-Jones AR, Di Napoli M, Goldstein JN. et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol 2015; 78: 54-62
    CrossrefPubMedGoogle Scholar
  • 61 Mayer SA, Brun NC, Begtrup K. et al. Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med 2008; 358: 2127-2137
    CrossrefPubMedGoogle Scholar
  • 62 Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999; 159: 2721-2724
    CrossrefPubMedGoogle Scholar
  • 63 Pollack Jr. CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-520
    CrossrefPubMedGoogle Scholar
  • 64 Held V, Eisele P, Eschenfelder CC. et al. Idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran. Case Rep Neurol 2016; 8: 224-228
    CrossrefPubMedGoogle Scholar
  • 65 Connolly SJ, Milling Jr. TJ, Eikelboom JW. et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131-1341
    CrossrefPubMedGoogle Scholar
  • 66 Portola Pharmaceuticals, I. 2016; Portola Pharmaceuticals receives complete response letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa).
    PubMed
  • 67 Ansell JE, Bakhru SH, Laulicht BE. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371: 2141-2142
    CrossrefPubMedGoogle Scholar
  • 68 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507
    CrossrefPubMedGoogle Scholar
  • 69 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579
    CrossrefPubMedGoogle Scholar
  • 70 Zahir H, Brown KS, Vandell AG. et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131: 82-90
    CrossrefPubMedGoogle Scholar
  • 71 Dibu JR, Weimer JM, Ahrens C. et al. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care 2016; 24: 413-419
    CrossrefPubMedGoogle Scholar
  • 72 van Ryn J, Sieger P, Kink-Eiband M. et al. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood 2009; 114: 440-440
    PubMedGoogle Scholar
  • 73 Wang X, Mondal S, Wang J. et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14: 147-154
    CrossrefPubMedGoogle Scholar
  • 74 Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive care unit is associated with reduced mortality rate after intracerebral hemorrhage. Crit Care Med 2001; 29: 635-640
    CrossrefPubMedGoogle Scholar
  • 75 Damian MS, Ben-Shlomo Y, Howard R. et al. The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barre syndrome admitted to critical care: an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database. Intensive Care Med 2013; 39: 1405-1412
    CrossrefPubMedGoogle Scholar
  • 76 Langhorne P, Fearon P, Ronning OM. et al. Stroke unit care benefits patients with intracerebral hemorrhage: systematic review and meta-analysis. Stroke 2013; 44: 3044-3049
    CrossrefPubMedGoogle Scholar
  • 77 Evans A, Perez I, Harraf F. et al. Can differences in management processes explain different outcomes between stroke unit and stroke-team care?. Lancet 2001; 358: 1586-1592
    CrossrefPubMedGoogle Scholar
  • 78 Mendelow AD, Gregson BA, Fernandes HM. et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365: 387-397
    CrossrefPubMedGoogle Scholar
  • 79 Mendelow AD, Gregson BA, Rowan EN. et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): A randomised trial. Lancet 2013; 382: 397-408
    CrossrefPubMedGoogle Scholar
  • 80 Mould WA, Carhuapoma JR, Muschelli J. et al. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke 2013; 44: 627-634
    CrossrefPubMedGoogle Scholar
  • 81 Hanley DF, Thompson RE, Muschelli J. et al. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): A randomised, controlled, open-label, phase 2 trial. Lancet Neurol 2016; 15: 1228-1237
    CrossrefPubMedGoogle Scholar
  • 82 Staykov D, Schwab S. Clearing bloody cerebrospinal fluid: Clot lysis, neuroendoscopy and lumbar drainage. Curr Opin Crit Care 2013; 19: 92-100
    CrossrefPubMedGoogle Scholar
  • 83 Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 2009; 40: 1533-1538
    CrossrefPubMedGoogle Scholar
  • 84 Staykov D, Huttner HB, Struffert T. et al. Intraventricular fibrinolysis and lumbar drainage for ventricular hemorrhage. Stroke 2009; 40: 3275-3280
    CrossrefPubMedGoogle Scholar
  • 85 Huttner HB, Nagel S, Tognoni E. et al. Intracerebral hemorrhage with severe ventricular involvement: Lumbar drainage for communicating hydrocephalus. Stroke 2007; 38: 183-187
    CrossrefPubMedGoogle Scholar
  • 86 Staykov D, Kuramatsu JB, Bardutzky J. et al. Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: A randomized trial and individual patient data meta-analysis. Ann Neurol 2016; 81: 93-103
    PubMedGoogle Scholar
  • 87 Chen CC, Liu CL, Tung YN. et al. Endoscopic surgery for intraventricular hemorrhage (IVH) caused by thalamic hemorrhage: Comparisons of endoscopic surgery and external ventricular drainage (EVD) surgery. World Neurosurg 2011; 75: 264-268
    CrossrefPubMedGoogle Scholar
  • 88 Volbers B, Willfarth W, Kuramatsu JB. et al. Impact of perihemorrhagic edema on short-term outcome after intracerebral hemorrhage. Neurocrit Care 2016; 24: 404-412
    CrossrefPubMedGoogle Scholar
  • 89 Murthy SB, Moradiya Y, Dawson J. et al. Perihematomal edema and functional outcomes in intracerebral hemorrhage: Influence of hematoma volume and location. Stroke 2015; 46: 3088-3092
    CrossrefPubMedGoogle Scholar
  • 90 Gebel Jr. JM, Jauch EC, Brott TG. et al. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002; 33: 2631-2635
    CrossrefPubMedGoogle Scholar
  • 91 Kuramatsu JB, Huttner HB, Schwab S. Advances in the management of intracerebral hemorrhage. J Neural Transm (Vienna) 2013; 120 (Suppl. 01) S35-S41
    CrossrefPubMedGoogle Scholar
  • 92 Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006; 5: 53-63
    CrossrefPubMedGoogle Scholar
  • 93 Rincon F, Mayer SA. Novel therapies for intracerebral hemorrhage. Curr Opin Crit Care 2004; 10: 94-100
    CrossrefPubMedGoogle Scholar
  • 94 Wang X, Arima H, Yang J. et al. Mannitol and outcome in intracerebral hemorrhage: propensity score and multivariable intensive blood pressure reduction in acute cerebral hemorrhage trial 2 results. Stroke 2015; 46: 2762-2767
    CrossrefPubMedGoogle Scholar
  • 95 Yu Y, Zhao W, Zhu C. et al. The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One 2015; 10: e0122371
    CrossrefPubMedGoogle Scholar
  • 96 Volbers B, Herrmann S, Willfarth W. et al. Impact of hypothermia initiation and duration on perihemorrhagic edema evolution after intracerebral emorrhage. Stroke 2016; 47: 2249-2255
    CrossrefPubMedGoogle Scholar
  • 97 Zheng D, Arima H, Heeley E. et al. Ambient temperature and volume of perihematomal edema in acute intracerebral haemorrhage: the INTERACT1 study. Int J Stroke 2015; 10: 25-27
    PubMedGoogle Scholar
  • 98 Fung C, Murek M, Klinger-Gratz PP. et al. Effect of decompressive craniectomy on perihematomal edema in patients with intracerebral hemorrhage. PLoS One 2016; 11: e0149169
    CrossrefPubMedGoogle Scholar
  • 99 Geeganage CM, Sprigg N, Bath MW. et al. Balance of symptomatic pulmonary embolism and symptomatic intracerebral hemorrhage with low-dose anticoagulation in recent ischemic stroke: A systematic review and meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis 2013; 22: 1018-1027
    CrossrefPubMedGoogle Scholar
  • 100 Munoz-Venturelli P, Wang X, Lavados PM. et al. Prophylactic heparin in acute intracerebral hemorrhage: a propensity score-matched analysis of the INTERACT2 study. Int J Stroke 2016; 11: 549-556
    CrossrefPubMedGoogle Scholar
  • 101 Dennis M, Sandercock PA, Reid J. et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): A multicentre, randomised controlled trial. Lancet 2009; 373: 1958-1965
    CrossrefPubMedGoogle Scholar
  • 102 Dennis M, Sandercock P, Reid J. et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): A multicentre randomised controlled trial. Lancet 2013; 382: 516-524
    CrossrefPubMedGoogle Scholar